Jennifer M. Suga

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Michael Gnant, Amylou C. Dueck, Sophie Frantal et al. · Journal of Clinical Oncology · 2021 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study

Nilofer S. Azad, Robert J. Gray, Michael J. Overman et al. · Journal of Clinical Oncology · 2019 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Qian Shi, Jennifer J. Knox et al. · JAMA Oncology · 2019 · 120 citations · Full text

Medicine, Oncology, Pharmacotherapy +17